Evidence map›Paper›PMID 42232791›Full record

ArticleLiver cancer2026

Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma.

Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji and 49 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

59 authors.

Atsushi HiraokaDepartment of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Toshifumi TadaDepartment of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
Masashi HirookaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Kazuya KariyamaDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Joji TaniDepartment of Gastroenterology and Neurology, Kagawa University, Takamatsu, Japan.
Masanori AtsukawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Koichi TakaguchiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Ei ItobayashiDepartment of Gastroenterology, Asahi General Hospital, Asahi, Japan.
Takashi NishimuraDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Kunihiko TsujiCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Toru IshikawaDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Kazuto TajiriDepartment of Gastroenterology, Toyama University Hospital, Toyama, Japan.
Hironori TanakaTakarazuka City Hospital, Department of Gastroenterology, Hyogo, Japan.
Hidenori ToyodaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Chikara OgawaDepartment of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Satoru KakizakiDepartment of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Atsushi NaganumaDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.
Hisashi KosakaDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Tomomitsu MatonoDepartment of Gastroenterology, Harima Himeji General Medical Center, Himeji, Japan.
Hidekatsu KurodaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.
Yutaka YataDepartment of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
Hiroki NishikawaDepartment of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
Michitaka ImaiDepartment of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Tomoko AokiDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
Hideyuki TamaiDepartment of Hepatology, Wakayama Rosai Hospital, Wakayama, Japan.
Shohei KomatsuDepartment of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Takanori MatsuuraDivision of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Yoshihide UedaDepartment of Gastroenterology, Kakogawa City Hospital, Kakogawa, Japan.
Soo Ki KimDepartment of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.
Hideko OhamaDepartment of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Fujimasa TadaDepartment of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Shinichiro NakamuraDepartment of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
Yoshiko NakamuraDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Osamu YoshidaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Kazuhiro NousoDepartment of Gastroenterology, Okayama City Hospital, Okayama, Japan.
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Kagawa University, Takamatsu, Japan.
Norio ItokawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Tomomi OkuboDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Taeang AraiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Akemi TsutsuiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Takuya NaganoDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Shinya FukunishiDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Kazunari TanakaCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Yuichi KoshiyamaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Yuki KanayamaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Hidenao NoritakeHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hirayuki EnomotoDepartment of Gastroenterology, Hyogo Medical University, Nishinomiya, Japan.
Kosuke MatsuiDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Masaki KaiboriDepartment of Hepatobiliary Surgery, Kansai Medical University, Hirakata, Japan.
Jumpei OkamuraDepartment of Hepatology, Wakayama Rosai Hospital, Wakayama, Japan.
Takumi FukumotoDepartment of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Takashi KumadaFaculty of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
RELPEC Group
HCC 48 Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Atezolizumab plus bevacizumab (Atez/Bev) was the first immune checkpoint inhibitor regimen approved in 2020 for unresectable hepatocellular carcinoma (uHCC), followed by durvalumab plus tremelimumab (Dur/Tre) in 2023. There is very little data available comparing the efficacy and safety of Atez/Bev with those of Dur/Tre. This study aimed to clarify the therapeutic outcomes and safety of Atez/Bev and Dur/Tre. Methods: We retrospectively analyzed patients with uHCC (BCLC-B/C and Child-Pugh class A) treated with Atez/Bev ( Results: The objective response rate and disease control rate were comparable between the Atez/Bev and Dur/Tre groups (31.8%/71.9% vs. 28.7%/63.6%, Conclusion: Although Atez/Bev was associated with a longer PFS, OS did not differ significantly between Atez/Bev and Dur/Tre. This dissociation between PFS and OS may reflect differences in disease biology, treatment sequencing, and post-progression management rather than intrinsic superiority of either regimen. These findings highlight the importance of individualized treatment selection and careful consideration of tumor characteristics and hepatic reserve when choosing first-line immunotherapy for uHCC.

Indexed as

Atezolizumab plus bevacizumabDurvalumab plus tremelimumabHepatocellular carcinomaImmune checkpoint inhibitor

Identifiers

PMID42232791
PMCPMC13225849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.